The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer

• Published in: Gynecologic oncology Vol. 100; no. 2; pp. 412 - 416
• Main Authors: Matsumoto, Koji, Katsumata, Noriyuki, Yamanaka, Yasuhiro, Yonemori, Kan, Kohno, Tsutomu, Shimizu, Chikako, Andoh, Masashi, Fujiwara, Yasuhiro
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2006
• Subjects: Adult; Aged; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Camptothecin - administration & dosage; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds - pharmacology; Ovarian cancer; Ovarian Neoplasms - drug therapy; Platinum-resistant; Retrospective Studies; Second line treatment; Taxanes-resistant; Taxoids - pharmacology; Weekly schedule; Irinotecan; Second line treatment; Taxanes-resistant; Ovarian cancer; Platinum-resistant; Weekly schedule

Irinotecan is one of the drugs that might be effective against platinum- and taxanes-resistant epithelial ovarian cancer. We investigated efficacy and safety of the weekly dosing schedule of irinotecan. From September 2001 to March 2003, 28 eligible patients who have histologically confirmed epithel...